Drugs / Quadrivalent HPV recombinant vaccine
Quadrivalent HPV recombinant vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05027776 | Sep 2021 → Nov 2023 overdue | anogenital human papillomavirus infection, cervical carcinoma, cervical intraepithelial neoplasia grade 2/3, vaginal cancer | Shanghai Bovax Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent HPV recombinant vaccine | “This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years” NCT05027776 ↗ |
| Known as | Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) | “Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A...” NCT05027776 ↗ |
| Modality | Vaccine | “This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years” NCT05027776 ↗ |
| Route | Intramuscular | “Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.” NCT05027776 ↗ |